Impact of uricosurics on mortality outcomes in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

Kow CS 1 , Ramachandram DS 2 , Hasan SS 3 , Thiruchelvam K 1

Affiliations 

  • 1 School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia
  • 2 School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia
  • 3 School of Applied Sciences, University of Huddersfield, United Kingdom
Int J Pharm Pract, 2024 May 07;32(3):259-264.
PMID: 38438314 DOI: 10.1093/ijpp/riae003

Abstract

OBJECTIVES: To determine risks associated with uricosurics in COVID-19 patients.

METHODS: A systematic review and meta-analysis was conducted by systematically searching electronic databases.

KEY FINDINGS: The pooled analysis of the included trials revealed that the use of uricosurics was not associated with the risk of mortality (pooled odds ratio [OR] = 1.03, 95% confidence interval [CI]: 0.94-1.12). However, there is a potential mortality benefit associated with the use of ascorbic acid (pooled OR = 0.78, 95% CI: 0.65-0.94).

CONCLUSIONS: The findings confirmed the safety of uricosurics in COVID-19 patients, despite their potential to cause uric acid excretion, which may possess antioxidant properties.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications